Axovant Sciences Company Profile (NYSE:AXON)

About Axovant Sciences (NYSE:AXON)

Axovant Sciences logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer's disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company's pipeline also includes RVT-103 and RVT-104.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSE:AXON
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.26342 billion
  • Outstanding Shares: 106,400,000
Average Prices:
  • 50 Day Moving Avg: $22.68
  • 200 Day Moving Avg: $19.46
  • 52 Week Range: $11.01 - $26.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.92 per share
  • Price / Book: 10.94
  • EBIDTA: ($207,250,000.00)
  • Return on Equity: -120.65%
  • Return on Assets: -87.29%
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 6.01%
  • Quick Ratio: 6.01%
  • Average Volume: 518,642 shs.
  • Beta: 0.41
  • Short Ratio: 7.32

Frequently Asked Questions for Axovant Sciences (NYSE:AXON)

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd. (NYSE:AXON) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.12. View Axovant Sciences' Earnings History.

When will Axovant Sciences make its next earnings announcement?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Axovant Sciences.

Where is Axovant Sciences' stock going? Where will Axovant Sciences' stock price be in 2017?

10 analysts have issued 12-month price targets for Axovant Sciences' shares. Their forecasts range from $7.50 to $40.00. On average, they expect Axovant Sciences' share price to reach $29.17 in the next year. View Analyst Ratings for Axovant Sciences.

What are analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (7/11/2017)
  • 2. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:

  • Marion McCourt, President, Chief Operating Officer
  • David T. Hung M.D., Chief Executive Officer, Director
  • Gregory M. Weinhoff M.D., Chief Financial Officer
  • Vivek Ramaswamy, Director, Chief Executive Officer - Roivant Sciences
  • Mark Altmeyer, President of Axovant Sciences GmbH and Chief Commercial Officer
  • Eric Floyd Ph.D., Senior Vice President - Regulatory Affairs
  • Ilise Lombardo M.D., Senior Vice President - Clinical Research
  • Thomas Templeman Ph.D., Senior Vice President - Pharmaceutical Operations and Quality Assurance
  • Mark Wadley, Senior Vice President, US Business
  • Samina Bari, Vice President - Corporate Communications

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences stock?

Axovant Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.74%), Capital Research Global Investors (3.25%), Janus Henderson Group PLC (1.94%), Franklin Resources Inc. (1.36%), State Street Corp (0.51%) and PointState Capital LP (0.33%). Company insiders that own Axovant Sciences stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Who sold Axovant Sciences stock? Who is selling Axovant Sciences stock?

Axovant Sciences' stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Franklin Resources Inc., VHCP Management II LLC, Artal Group S.A., Candriam Luxembourg S.C.A., Nationwide Fund Advisors, Ameriprise Financial Inc. and Strs Ohio. View Insider Buying and Selling for Axovant Sciences.

Who bought Axovant Sciences stock? Who is buying Axovant Sciences stock?

Axovant Sciences' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Capital Research Global Investors, State Street Corp, Ratan Capital Management LP, OxFORD Asset Management LLP, Prudential Financial Inc. and Federated Investors Inc. PA. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy Axovant Sciences stock?

Shares of Axovant Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of Axovant Sciences stock can currently be purchased for approximately $21.01.

MarketBeat Community Rating for Axovant Sciences (NYSE AXON)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Axovant Sciences (NYSE:AXON) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $29.17 (38.82% upside)

Analysts' Ratings History for Axovant Sciences (NYSE:AXON)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$40.00LowView Rating Details
6/21/2017Cowen and CompanyReiterated RatingOutperform$30.00MediumView Rating Details
6/14/2017CIBCBoost Price TargetOutperform -> Outperform$26.00 -> $30.00HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$26.00 -> $30.00MediumView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$32.00LowView Rating Details
2/14/2017HC WainwrightSet Price TargetBuy$35.00N/AView Rating Details
12/20/2016Robert W. BairdReiterated RatingPositive$29.00N/AView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
11/8/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Evercore ISIReiterated RatingBuy$29.00N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
2/3/2016Chardan CapitalReiterated RatingSell$8.00N/AView Rating Details
(Data available from 8/19/2015 forward)


Earnings History for Axovant Sciences (NYSE:AXON)
Earnings by Quarter for Axovant Sciences (NYSE:AXON)
Earnings History by Quarter for Axovant Sciences (NYSE AXON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.58)N/AView Earnings Details
10/23/2017N/AView Earnings Details
8/7/2017Q1 2018($0.53)($0.65)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Axovant Sciences (NYSE:AXON)
Current Year EPS Consensus Estimate: $-2.32 EPS
Next Year EPS Consensus Estimate: $-3.01 EPS


Dividend History for Axovant Sciences (NYSE:AXON)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Axovant Sciences (NYSE:AXON)
Insider Ownership Percentage: 72.50%
Institutional Ownership Percentage: 94.54%
Insider Trades by Quarter for Axovant Sciences (NYSE:AXON)
Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)
Insider Trades by Quarter for Axovant Sciences (NYSE:AXON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.98View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Axovant Sciences (NYSE:AXON)
Latest Headlines for Axovant Sciences (NYSE:AXON)
DateHeadline logoAxovant Sciences Target of Unusually High Options Trading (AXON) - August 19 at 1:32 AM logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock - Nasdaq - August 18 at 9:24 PM logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock - August 18 at 4:23 PM logoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd. - August 10 at 4:24 PM logoRoivant's Billion-Dollar Haul Shouldn't Buy Off Skepticism - August 10 at 4:24 PM logo[$$] SoftBank Leads $1.1 Billion Investment in Roivant Sciences - August 9 at 9:31 PM logoBiotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups - August 9 at 4:28 PM logoA 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life - August 9 at 4:28 PM logoAxovant Sciences Ltd. (NYSE:AXON) Posts Earnings Results, Misses Estimates By $0.12 EPS - August 8 at 10:51 AM logoAxovant Announces Fiscal First Quarter Financial Results and Corporate Updates - August 7 at 5:03 PM logoAxovant reports 1Q loss - August 7 at 5:03 PM logoAxovant Sciences Ltd. (AXON) to Release Earnings on Monday - August 7 at 7:50 AM logoAxovant Sciences Ltd. (NYSE:AXON) Receives Consensus Rating of "Buy" from Analysts - August 4 at 8:52 AM logo Analysts Expect Axovant Sciences Ltd. (AXON) to Announce -$0.52 Earnings Per Share - August 3 at 8:08 AM logoWill Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug? - July 26 at 4:53 PM logo-$0.54 Earnings Per Share Expected for Axovant Sciences Ltd. (AXON) This Quarter - July 11 at 10:16 PM logoAxovant Sciences Ltd. (AXON) Rating Lowered to Sell at Zacks Investment Research - July 11 at 5:26 PM logoAxovant Sciences Ltd. (NYSE:AXON) Coverage Initiated at Jefferies Group LLC - July 10 at 5:26 PM logoAxovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference - July 10 at 4:18 PM logoDermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman - July 10 at 4:18 PM logoAxovant Sciences Ltd. (NYSE:AXON) Given Consensus Recommendation of "Buy" by Brokerages - July 10 at 8:57 AM logoBiotech's IPO Uptick Is Nothing to Fear - July 8 at 8:58 PM logoBidaskClub Downgrades Axovant Sciences Ltd. (NYSE:AXON) to Hold - July 8 at 1:02 PM logoBiotech Stock Performance Review -- Vertex Pharma, VIVUS, Xbiotech, and Axovant Sciences - PR Newswire (press release) - June 30 at 10:10 PM logoEarnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings - June 29 at 5:21 PM logoAxovant Sciences Ltd. (AXON) Rating Reiterated by Cowen and Company - June 25 at 1:52 PM logoAxovant Sciences Ltd. (AXON) Lifted to Buy at BidaskClub - June 23 at 11:28 PM logoFeatured Company News - Juno Therapeutics Shared Updated Data for TRANSCEND NHL 001 Clinical Trial at the IMCL Conference in Switzerland - June 20 at 4:27 PM logoFDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies - June 19 at 9:44 AM logo Brokerages Anticipate Axovant Sciences Ltd. (AXON) Will Post Earnings of -$0.49 Per Share - June 15 at 10:20 PM logoRigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data - June 14 at 8:57 PM logoOppenheimer Holdings, Inc. Boosts Axovant Sciences Ltd. (AXON) Price Target to $30.00 - June 14 at 1:00 PM logoCIBC Reaffirms "Outperform" Rating for Axovant Sciences Ltd. (AXON) - June 14 at 12:28 PM logoAxovant Sciences Ltd. (AXON) Given "Outperform" Rating at Cowen and Company - June 13 at 7:16 PM logoAxovant Sciences Ltd. (AXON) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - June 13 at 2:26 PM logoAxovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates - June 13 at 1:17 PM logoAxovant reports 4Q loss - June 13 at 1:17 PM logoAxovant Sciences Ltd. (AXON) Given Average Rating of "Buy" by Brokerages - June 13 at 8:58 AM logoJefferies Group LLC Reiterates Buy Rating for Axovant Sciences Ltd (AXON) - June 9 at 5:08 PM logoAxovant Sciences (AXON) Appoints Patrick Machado to Board - - June 7 at 8:37 AM logoAxovant Announces Changes to Board of Directors - June 6 at 3:56 PM logoAxovant Strengthens Executive Team with Key Management Appointments - June 6 at 3:56 PM logoNotable Thursday Option Activity: CBI, AXON, ALRM - Nasdaq - June 1 at 9:07 PM logoCommit To Purchase Axovant Sciences At $12.50, Earn 103.3% Annualized Using Options - Nasdaq - May 26 at 4:05 PM logoAxovant Sciences Ltd (AXON) Given Consensus Recommendation of "Buy" by Brokerages - May 19 at 9:24 AM logo-$0.51 EPS Expected for Axovant Sciences Ltd (AXON) This Quarter - April 28 at 11:13 AM logoInsider Transactions Weekly Newsletter - April 26 at 4:05 PM logoAxovant Sciences Ltd (AXON) Given Average Recommendation of "Buy" by Analysts - April 24 at 11:36 AM logoCompany Spotlight: Axovant Sciences - April 22 at 10:21 AM logoCompany Spotlight: Axovant Sciences - Nasdaq - April 21 at 3:50 PM



Axovant Sciences (AXON) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by Staff